Not provided

GS-3107 (oral lenacapavir prodrug)

Not applicable (investigational; no brand name assigned)

Small molecule

Capsid inhibitor

GS-3107 is an investigational long-acting capsid inhibitor. It is an oral prodrug of lenacapavir. This capsid inhibitor is designed to convert to lenacapavir after oral administration, but with a pharmacokinetic profile engineered to increase oral bioavailability and support once-monthly oral dosing. The approach of using prodrug to optimise bioavailability is being used when parent molecules have limited oral absorption. By increasing oral bioavailability, lower doses are needed, which means smaller pills (including in fixed-dose combinations). It is intended as the oral component of a once-monthly oral treatment regimen with an integrase inhibitor partner still to be defined; a paediatric HIV-1 treatment study is also planned according to the company pipeline.

Investigational

The product is still in development.